What percentage of world imports are now affected by tariffs?

As of 2026, approximately 19.7% of world imports are affected by tariffs or other trade restriction measures introduced since 2009 — up sharply from 12.6% just one year earlier. This single-year jump of 7 percentage points is the largest such increase in recorded WTO history, driven primarily by US tariff expansions and retaliatory measures from China, the EU, and other trading partners. Global trade is increasingly fragmented by tariff barriers that did not exist a decade ago.

What is the US-India trade deal of 2026?

The US and India reached a bilateral trade framework in February 2026, with the US imposing an 18% tariff on most Indian goods (down from the initial threatened rates of 25-26%). India received preferential treatment versus baseline tariff levels in exchange for commitments on market access, intellectual property, and digital trade. However, US pharmaceutical tariffs on Indian goods are a separate track: the US threatened 100% tariffs on Indian pharmaceutical imports from July 31, 2026, which could devastate India's $8-9 billion annual pharma export to the US. Negotiations on pharma tariffs were ongoing as of June 2026.

What happened to the US Section 122 tariffs that were struck down?

The US Supreme Court struck down the Section 232/122 tariffs on certain product categories in February 2026, ruling that the executive branch had exceeded its authority. However, the Trump administration introduced replacement tariff mechanisms, and some bilateral deals (like the India-US 18% rate from February 2026) were negotiated in the context of these tariff threats. The legal situation around US tariff authority is complex: even as courts challenge some tariff mechanisms, new ones are introduced under different statutory authorities.

How do global tariffs affect Indian exporters?

India's major export categories face different tariff headwinds in 2026: (1) Pharmaceuticals — the 100% tariff threat from July 31, 2026 on Indian pharma exports to the US would affect India's $8-9B pharmaceutical export industry and companies like Sun Pharma, Cipla, Dr. Reddy's, and Aurobindo. (2) Gems and jewellery — affected by various destination-country tariff changes. (3) Textiles and apparel — facing increased competition from Vietnam, Bangladesh, and Cambodia as buyers diversify away from both India and China. (4) IT services — less directly affected by goods tariffs, but impacted by H-1B visa constraints and digital trade provisions. India is pushing to resolve the pharma tariff issue before July 31 as the priority.

Global trade growth slows to 0.5% in 2026 as tariffs cover 19.7% of world imports

Q: How fast is global trade growing in 2026?

The WTO estimates world merchandise trade growth of only 0.5% in 2026, down sharply from 2.4% in 2025. This near-stagnation in global trade is the result of multiple simultaneous headwinds: US tariff increases, retaliatory measures by trading partners, the Iran conflict disrupting shipping routes, and weaker global demand from high energy costs. The UNCTAD (UN Trade and Development) estimates trade in services is growing faster than goods, but overall trade expansion is the weakest since the COVID recovery.

The era of free and open global trade, which characterised the post-WTO period from 1995 to 2019, is over. In 2026, approximately 19.7% of world imports are affected by tariffs and trade restriction measures — up from 12.6% just one year prior, the sharpest single-year jump in WTO history. As a consequence, the WTO estimates global merchandise trade growth at a near-stagnant 0.5% in 2026, down from 2.4% in 2025. The world is not deglobalising — but it is fragmenting into competing trade blocs, bilateral deal-making, and sector-specific protective barriers.

For India, navigating this environment requires managing an 18% tariff on goods exports to the US, a potential 100% pharma tariff from July 31, 2026, and simultaneously competing for manufacturing investment with Vietnam, Mexico, and Bangladesh in a more protectionist world.

What Happened

The tariff explosion of 2025-2026. The Trump administration's return to office in January 2025 brought a rapid expansion of US tariff policy. Initial blanket tariffs, a specific Section 122 tariff mechanism, and bilateral deals were layered in rapid succession. The legal and trade landscape became extremely complex:

February 2026: US Supreme Court struck down Section 232/122 tariffs on constitutional grounds (executive authority overreach)
February 2026: US-India bilateral trade deal at 18% tariff on most Indian goods
May 2026: Supreme Court struck down replacement Section 122 tariff mechanism
July 31, 2026: Threatened 100% tariff on Indian pharmaceutical imports (deadline still outstanding)
EU-US deal: EU agreed 15% tariff on most exports to US in exchange for US removing tariffs on EU industrial goods imports

The 19.7% coverage rate explained. WTO's measure of import coverage by trade restrictions includes tariffs, anti-dumping duties, countervailing duties, safeguard measures, and import quotas. The increase from 12.6% to 19.7% in one year reflects:

New US tariffs covering previously duty-free trade categories
Retaliatory tariffs by China, EU, Canada, and Mexico
India, Brazil, and others imposing safeguard duties on steel, aluminium, and specific agricultural products
Technology-sector controls (semiconductors, AI chips) that function as trade restrictions

WTO merchandise trade growth at 0.5% for 2026 is the weakest since the 2020 COVID shock. This compares to:

2024: +2.7% (post-tariff shock bounce)
2025: +2.4%
2026: +0.5%
Pre-2018 (pre-trade war) trend: 3-5% annually

Regional trade bloc formation. The global trade system is consolidating around three blocs:

US-allied bloc: US, EU (pending final deal), UK, Australia, Japan, South Korea, India
China-led bloc: China, Russia, much of ASEAN (through RCEP), parts of Africa and LatAm via BRI
Neutral/swing states: Brazil, Saudi Arabia, UAE, Mexico — maintaining ties with both blocs

Why This Matters for Investors

Indian pharma sector faces existential risk from July 31 deadline. India exports approximately $8-9 billion in pharmaceutical products annually to the US — India is the largest supplier of generic drugs to the American market, providing approximately 47% of all generic prescriptions filled in the US. A 100% tariff would make these generics uncompetitive, threatening:

Revenue for Sun Pharma, Cipla, Dr. Reddy's, Aurobindo Pharma, Lupin
Supply of affordable medicines in the US market (which depends on Indian generics)
Employment in India's pharmaceutical manufacturing sector

The 100% tariff threat is also partially a negotiating tactic — the US wants concessions from India on data localisation, intellectual property (pharmaceutical patents), and digital trade. Resolution before July 31 is possible but not guaranteed.

The 18% US tariff on Indian goods has a differentiated impact by sector. Indian goods facing 18% US tariffs are less competitive versus goods from countries with lower bilateral tariff deals. Vietnam (with a separate deal), Cambodia (GSP-like treatment), and Mexico (within USMCA) all face lower US tariff rates, making India's manufacturing exports to the US relatively more expensive. For India's ambition to capture manufacturing supply chains from China, this tariff disadvantage matters.

The EU 15% tariff deal provides US market access for European goods at a rate lower than India's 18%. This creates a competitive advantage for European manufacturers in the US market versus Indian suppliers in overlapping product categories (chemicals, engineering goods, medical devices).

For Indian IT services companies, goods tariffs are largely irrelevant — services trade is governed by different WTO rules (GATS) and visa/immigration policies (H-1B). However, if digital trade provisions in bilateral deals include data localisation requirements or restrictions on cross-border data flows, it could create operational complications for Indian IT companies serving US clients with India-based teams.

Market Reaction

Global trade stocks (logistics, shipping, export-heavy manufacturers) have underperformed in 2026 as slower trade growth reduces volumes and margins. The Container Shipping Index shows freight rates normalised from post-COVID highs but remain elevated due to Hormuz rerouting costs and structural tariff-induced rebalancing.

India's goods export companies have faced stock pressure from tariff uncertainty. Sun Pharma, Dr. Reddy's, and Cipla saw share price volatility in June 2026 as the July 31 pharma tariff deadline approached. The pharma sector is watching the India-US negotiation outcome as the single most important near-term catalyst.

Sectors benefiting from trade fragmentation include Indian companies competing with Chinese suppliers in third-country markets (where China is facing retaliatory tariffs from the EU and others), and companies that can position as US allies' preferred suppliers for critical goods.

What Investors Should Watch

India-US pharma tariff resolution by July 31. This is the most acute near-term trade risk for Indian equities. If resolved (most likely 18% tariff aligned with the general India-US deal), Indian pharma stocks would rally significantly from current uncertainty-depressed levels. If the 100% tariff takes effect, it would be a sector-defining negative event.

WTO Appellate Body restoration. The US blocking of WTO Appellate Body appointments has left the dispute resolution system non-functional since 2019. Without a functioning WTO court, trade disputes cannot be formally adjudicated — bilateral deals and power dynamics replace multilateral rules. Watch for any breakthrough on WTO reform that could restore a rules-based trade adjudication system.

China's retaliatory tariff evolution. As the US maintained elevated tariffs on Chinese goods, China has been calibrating retaliatory tariffs on US agricultural products, services, and technology companies operating in China. If this escalation intensifies in H2 2026, it would further reduce global trade growth below the 0.5% WTO estimate.

Risks to Monitor

Tariff escalation in autos and technology. The EU is considering additional tariffs on Chinese EVs (already imposed in late 2024) and China is considering retaliatory measures on European and American luxury cars and aeroplanes. A transatlantic auto and tech tariff war would reduce global trade further and create significant industrial disruption.

India's trade position between blocs. India's dual membership in BRICS and its strategic partnership with the US creates a diplomatic tightrope. If the US explicitly demands India choose between the BRICS payment system and access to the US market (or technology), India would face a binary choice with enormous economic consequences.

Global supply chain reconfiguration costs. The shift from a China-centric to a diversified supply chain requires massive capital expenditure in new manufacturing locations. This reconfiguration takes years and involves significant upfront costs, corporate earnings volatility, and market disruption before the benefits materialise. In 2026, many companies are mid-reconfiguration — facing costs without yet having the revenue benefits.

The 19.7% tariff coverage of global imports is not a temporary blip — it reflects a structural shift in how nations perceive trade: less as comparative advantage and more as strategic competition. For investors, this means supply chain, sector allocation, and geographic exposure decisions need to account for a permanently more protectionist world than the one that existed from 1995 to 2018.

Frequently Asked Questions

How fast is global trade growing in 2026?

0.5% for merchandise trade, the WTO's 2026 estimate — down from 2.4% in 2025. The slowdown reflects tariff barriers, Iran conflict shipping disruption, and weaker global demand.

What percentage of world imports face tariffs in 2026?

19.7%, up from 12.6% the prior year — the largest single-year increase in WTO history. Includes US tariffs, retaliatory measures, and sectoral trade restrictions globally.

What is India's US tariff situation?

General goods: 18% tariff agreed February 2026. Pharmaceuticals: threatened 100% tariff from July 31, 2026, still under negotiation. Indian pharma ($8-9B US exports) faces the most acute risk.

What is the EU-US trade deal?

EU agreed 15% tariff on most exports to the US, in exchange for US removing tariffs on EU industrial goods imports. Still being finalised as of June 2026.

How does protectionism affect India's manufacturing ambitions?

At 18% tariffs, Indian goods are more expensive in the US than goods from USMCA (Mexico 0%) or some ASEAN nations with separate deals, creating competitive disadvantage for India's "China Plus One" manufacturing story.